Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04804891 · ClinicalTrials.gov registry record · Phase 1
Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation
A Phase 1 study of Intestinal Transplantation, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT04804891 is a Phase 1 study of Intestinal Transplantation that is actively recruiting participants, run by Columbia University. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04804891, a Phase 1 study of Intestinal Transplantation, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safety and feasibility of giving intestinal transplant patients CD34+ stem cells (the cells that make all the types of blood cells) obtained from their organ donor's bone marrow. The goal of this is to develop a post-transplant treatment strategy that controls rejection while reducing the high risk of infection and malignant disease associated with the high levels of immunosuppression medication(s) that intestinal and multi-organ transplant patients must take. Infusion of bone marrow cells from the same donor of the transplanted organ(s) could promote a state called "mixed chimerism" in which both donor cells and recipient cells coexist in the body with the ultimate goal of minimizing the amount of immunosuppression medication(s) needed.
Conditions Studied
Interventions
- BIOLOGICAL Cell Therapy
Study Locations (1)
New York
- Columbia University Irving Medical Center/NYP - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04804891
The ClinicalTrials.gov registry entry for NCT04804891 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intestinal Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Cell Therapy is the first listed.
NCT04804891 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04804891 about?
NCT04804891 is a clinical study titled "Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation". The purpose of this study is to investigate the safety and feasibility of giving intestinal transplant patients CD34+ stem cells (the cells that make all the types of blood cells) obtained from their organ donor's bone marrow. The goal of this is to develop a post-transplant treatment strategy that ...
What is the current status of trial NCT04804891?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-10-22. Estimated completion is 2028-12.
What conditions does trial NCT04804891 study?
This clinical trial studies the following conditions: Intestinal Transplantation.
What interventions are being tested in trial NCT04804891?
The interventions under investigation include: Cell Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04804891?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04804891 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.